<!DOCTYPE html><html lang="en" class="dark"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1"/><link rel="preload" href="/_next/static/media/e4af272ccee01ff0-s.p.woff2" as="font" crossorigin="" type="font/woff2"/><link rel="stylesheet" href="/_next/static/css/8d323862949ffad9.css" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" href="/_next/static/chunks/webpack-d2cf98d9cef4ff37.js"/><script src="/_next/static/chunks/ceb5afef-fd730bca4742d10d.js" async=""></script><script src="/_next/static/chunks/156-5c70558397be49ef.js" async=""></script><script src="/_next/static/chunks/main-app-f896963268641fe0.js" async=""></script><script src="/_next/static/chunks/863-822c2cde35e02348.js" async=""></script><script src="/_next/static/chunks/app/layout-fb78cfc571d4c3d6.js" async=""></script><title>Unloxcyt Market Survey - Interactive Presentation</title><meta name="description" content="Comprehensive market analysis of Cosibelimab-ipdl for advanced cSCC"/><meta name="next-size-adjust"/><script src="/_next/static/chunks/polyfills-42372ed130431b0a.js" noModule=""></script></head><body class="__className_f367f3 h-1080px w-1920px"><!--$!--><template data-dgst="BAILOUT_TO_CLIENT_SIDE_RENDERING"></template><!--/$--><div class="relative overflow-hidden w-[1920px] h-[1080px] bg-gradient-to-br from-slate-900 to-slate-700 text-white"><div class="flex flex-col w-full h-full"><div class="flex-none bg-slate-800/90 p-6 flex items-center gap-4"><svg xmlns="http://www.w3.org/2000/svg" width="48" height="48" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-building2 text-blue-400"><path d="M6 22V4a2 2 0 0 1 2-2h8a2 2 0 0 1 2 2v18Z"></path><path d="M6 12H4a2 2 0 0 0-2 2v6a2 2 0 0 0 2 2h2"></path><path d="M18 9h2a2 2 0 0 1 2 2v9a2 2 0 0 1-2 2h-2"></path><path d="M10 6h4"></path><path d="M10 10h4"></path><path d="M10 14h4"></path><path d="M10 18h4"></path></svg><h1 class="text-6xl font-bold text-white">Company &amp; Product Overview</h1></div><div class="flex-1 min-h-0 grid grid-cols-[2fr_3fr] gap-8 p-8"><div class="flex flex-col gap-6"><div class="bg-slate-800/85 p-6 rounded-lg"><h3 class="text-4xl font-bold text-white mb-6">Corporate Evolution</h3><div class="space-y-4"><div class="flex items-center gap-4"><div class="w-16 h-16 bg-purple-500 rounded-full flex items-center justify-center"><p class="text-xl font-bold">2014</p></div><p class="text-2xl">Checkpoint Therapeutics founded by Fortress Biotech</p></div><div class="ml-8 w-0.5 h-8 bg-blue-400"></div><div class="flex items-center gap-4"><div class="w-16 h-16 bg-purple-500 rounded-full flex items-center justify-center"><p class="text-lg font-bold">Dec 2024</p></div><p class="text-2xl">Unloxcyt FDA approval for advanced cSCC</p></div><div class="ml-8 w-0.5 h-8 bg-blue-400"></div><div class="flex items-center gap-4"><div class="w-16 h-16 bg-purple-500 rounded-full flex items-center justify-center"><p class="text-lg font-bold">May 2025</p></div><p class="text-2xl">Sun Pharma acquisition ($416M total value)</p></div></div><p class="text-xl text-gray-300 mt-6"><strong>Headquarters:</strong> Waltham, Massachusetts, USA</p></div><div class="bg-slate-800/85 p-6 rounded-lg"><h3 class="text-4xl font-bold text-orange-400 mb-6">Acquisition Structure</h3><div class="space-y-3"><div class="flex justify-between"><p class="text-2xl text-gray-300">Upfront Cash:</p><p class="text-2xl font-bold">$355M ($4.10/share)</p></div><div class="flex justify-between"><p class="text-2xl text-gray-300">Contingent CVR:</p><p class="text-2xl font-bold">Up to $4.8M (EU approvals)</p></div><div class="flex justify-between"><p class="text-2xl text-gray-300">Fortress Royalty:</p><p class="text-2xl font-bold">2.5% on net sales</p></div></div><p class="text-xl text-gray-300 italic mt-4">Sun Pharma gains specialty oncology-dermatology asset with global commercialization infrastructure</p></div></div><div class="bg-slate-800/85 p-6 rounded-lg"><h2 class="text-5xl font-bold bg-gradient-to-r from-blue-400 to-purple-400 bg-clip-text text-transparent mb-2">Unloxcyt (cosibelimab-ipdl)</h2><h3 class="text-3xl text-green-400 mb-8">First and Only FDA-Approved PD-L1 Inhibitor for Advanced cSCC</h3><h4 class="text-4xl font-bold text-white mb-4">Mechanism of Action</h4><div class="space-y-3 mb-8"><div class="flex items-start gap-3"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-circle-check-big text-blue-400 mt-1"><path d="M21.801 10A10 10 0 1 1 17 3.335"></path><path d="m9 11 3 3L22 4"></path></svg><p class="text-2xl">Human IgG1 monoclonal antibody targeting PD-L1</p></div><div class="flex items-start gap-3"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-circle-check-big text-blue-400 mt-1"><path d="M21.801 10A10 10 0 1 1 17 3.335"></path><path d="m9 11 3 3L22 4"></path></svg><p class="text-2xl">Dual action: Blocks PD-L1/PD-1 and PD-L1/B7.1 interactions</p></div><div class="flex items-start gap-3"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-circle-check-big text-blue-400 mt-1"><path d="M21.801 10A10 10 0 1 1 17 3.335"></path><path d="m9 11 3 3L22 4"></path></svg><p class="text-2xl">Induces antibody-dependent cell-mediated cytotoxicity (ADCC)</p></div></div><h4 class="text-4xl font-bold text-white mb-4">Clinical Efficacy (Study CK-301-101)</h4><div class="grid grid-cols-2 gap-4 mb-8"><div class="bg-slate-700/50 p-4 rounded-lg"><p class="text-xl text-gray-300">Metastatic cSCC ORR</p><p class="text-3xl font-bold text-green-400">47%</p></div><div class="bg-slate-700/50 p-4 rounded-lg"><p class="text-xl text-gray-300">Locally Advanced ORR</p><p class="text-3xl font-bold text-green-400">48%</p></div><div class="bg-slate-700/50 p-4 rounded-lg"><p class="text-xl text-gray-300">Median Duration (Met)</p><p class="text-2xl font-bold text-green-400">Not reached</p></div><div class="bg-slate-700/50 p-4 rounded-lg"><p class="text-xl text-gray-300">12-Month Response</p><p class="text-2xl font-bold text-green-400">75.4% / 88.2%</p></div></div><div class="space-y-4"><div><p class="text-2xl font-bold text-white mb-2">Indication:</p><p class="text-xl text-gray-300">Metastatic or locally advanced cutaneous squamous cell carcinoma in adults not candidates for curative surgery or radiation</p></div><div><p class="text-2xl font-bold text-white mb-2">Dosing:</p><p class="text-xl text-gray-300">1,200 mg IV infusion every 3 weeks</p></div></div></div></div><div class="flex-none p-4 text-right"><p class="text-xl text-gray-400">3</p></div></div></div><script src="/_next/static/chunks/webpack-d2cf98d9cef4ff37.js" async=""></script><script>(self.__next_f=self.__next_f||[]).push([0]);self.__next_f.push([2,null])</script><script>self.__next_f.push([1,"1:HL[\"/_next/static/media/e4af272ccee01ff0-s.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"type\":\"font/woff2\"}]\n2:HL[\"/_next/static/css/8d323862949ffad9.css\",\"style\"]\n"])</script><script>self.__next_f.push([1,"3:I[5616,[],\"\"]\n5:I[6146,[],\"\"]\n6:I[4411,[],\"\"]\n7:\"$Sreact.suspense\"\n8:I[7256,[\"863\",\"static/chunks/863-822c2cde35e02348.js\",\"185\",\"static/chunks/app/layout-fb78cfc571d4c3d6.js\"],\"KeyboardNavigation\"]\n9:I[5407,[\"863\",\"static/chunks/863-822c2cde35e02348.js\",\"185\",\"static/chunks/app/layout-fb78cfc571d4c3d6.js\"],\"SlideNavigation\"]\nb:I[7141,[],\"\"]\nc:[]\n"])</script><script>self.__next_f.push([1,"0:[\"$\",\"$L3\",null,{\"buildId\":\"DkpgZd6XOJjDaY981EGFp\",\"assetPrefix\":\"\",\"urlParts\":[\"\",\"pages\",\"3\"],\"initialTree\":[\"\",{\"children\":[\"pages\",{\"children\":[\"3\",{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],\"initialSeedData\":[\"\",{\"children\":[\"pages\",{\"children\":[\"3\",{\"children\":[\"__PAGE__\",{},[[\"$L4\",[\"$\",\"div\",null,{\"className\":\"relative overflow-hidden w-[1920px] h-[1080px] bg-gradient-to-br from-slate-900 to-slate-700 text-white\",\"children\":[\"$\",\"div\",null,{\"className\":\"flex flex-col w-full h-full\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex-none bg-slate-800/90 p-6 flex items-center gap-4\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":48,\"height\":48,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-building2 text-blue-400\",\"children\":[[\"$\",\"path\",\"1b4qmf\",{\"d\":\"M6 22V4a2 2 0 0 1 2-2h8a2 2 0 0 1 2 2v18Z\"}],[\"$\",\"path\",\"i71pzd\",{\"d\":\"M6 12H4a2 2 0 0 0-2 2v6a2 2 0 0 0 2 2h2\"}],[\"$\",\"path\",\"10jefs\",{\"d\":\"M18 9h2a2 2 0 0 1 2 2v9a2 2 0 0 1-2 2h-2\"}],[\"$\",\"path\",\"1itunk\",{\"d\":\"M10 6h4\"}],[\"$\",\"path\",\"tcdvrf\",{\"d\":\"M10 10h4\"}],[\"$\",\"path\",\"kelpxr\",{\"d\":\"M10 14h4\"}],[\"$\",\"path\",\"1ulq68\",{\"d\":\"M10 18h4\"}],\"$undefined\"]}],[\"$\",\"h1\",null,{\"className\":\"text-6xl font-bold text-white\",\"children\":\"Company \u0026 Product Overview\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex-1 min-h-0 grid grid-cols-[2fr_3fr] gap-8 p-8\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex flex-col gap-6\",\"children\":[[\"$\",\"div\",null,{\"className\":\"bg-slate-800/85 p-6 rounded-lg\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"text-4xl font-bold text-white mb-6\",\"children\":\"Corporate Evolution\"}],[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center gap-4\",\"children\":[[\"$\",\"div\",null,{\"className\":\"w-16 h-16 bg-purple-500 rounded-full flex items-center justify-center\",\"children\":[\"$\",\"p\",null,{\"className\":\"text-xl font-bold\",\"children\":\"2014\"}]}],[\"$\",\"p\",null,{\"className\":\"text-2xl\",\"children\":\"Checkpoint Therapeutics founded by Fortress Biotech\"}]]}],[\"$\",\"div\",null,{\"className\":\"ml-8 w-0.5 h-8 bg-blue-400\"}],[\"$\",\"div\",null,{\"className\":\"flex items-center gap-4\",\"children\":[[\"$\",\"div\",null,{\"className\":\"w-16 h-16 bg-purple-500 rounded-full flex items-center justify-center\",\"children\":[\"$\",\"p\",null,{\"className\":\"text-lg font-bold\",\"children\":\"Dec 2024\"}]}],[\"$\",\"p\",null,{\"className\":\"text-2xl\",\"children\":\"Unloxcyt FDA approval for advanced cSCC\"}]]}],[\"$\",\"div\",null,{\"className\":\"ml-8 w-0.5 h-8 bg-blue-400\"}],[\"$\",\"div\",null,{\"className\":\"flex items-center gap-4\",\"children\":[[\"$\",\"div\",null,{\"className\":\"w-16 h-16 bg-purple-500 rounded-full flex items-center justify-center\",\"children\":[\"$\",\"p\",null,{\"className\":\"text-lg font-bold\",\"children\":\"May 2025\"}]}],[\"$\",\"p\",null,{\"className\":\"text-2xl\",\"children\":\"Sun Pharma acquisition ($416M total value)\"}]]}]]}],[\"$\",\"p\",null,{\"className\":\"text-xl text-gray-300 mt-6\",\"children\":[[\"$\",\"strong\",null,{\"children\":\"Headquarters:\"}],\" Waltham, Massachusetts, USA\"]}]]}],[\"$\",\"div\",null,{\"className\":\"bg-slate-800/85 p-6 rounded-lg\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"text-4xl font-bold text-orange-400 mb-6\",\"children\":\"Acquisition Structure\"}],[\"$\",\"div\",null,{\"className\":\"space-y-3\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex justify-between\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-2xl text-gray-300\",\"children\":\"Upfront Cash:\"}],[\"$\",\"p\",null,{\"className\":\"text-2xl font-bold\",\"children\":\"$$355M ($4.10/share)\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex justify-between\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-2xl text-gray-300\",\"children\":\"Contingent CVR:\"}],[\"$\",\"p\",null,{\"className\":\"text-2xl font-bold\",\"children\":\"Up to $4.8M (EU approvals)\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex justify-between\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-2xl text-gray-300\",\"children\":\"Fortress Royalty:\"}],[\"$\",\"p\",null,{\"className\":\"text-2xl font-bold\",\"children\":\"2.5% on net sales\"}]]}]]}],[\"$\",\"p\",null,{\"className\":\"text-xl text-gray-300 italic mt-4\",\"children\":\"Sun Pharma gains specialty oncology-dermatology asset with global commercialization infrastructure\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"bg-slate-800/85 p-6 rounded-lg\",\"children\":[[\"$\",\"h2\",null,{\"className\":\"text-5xl font-bold bg-gradient-to-r from-blue-400 to-purple-400 bg-clip-text text-transparent mb-2\",\"children\":\"Unloxcyt (cosibelimab-ipdl)\"}],[\"$\",\"h3\",null,{\"className\":\"text-3xl text-green-400 mb-8\",\"children\":\"First and Only FDA-Approved PD-L1 Inhibitor for Advanced cSCC\"}],[\"$\",\"h4\",null,{\"className\":\"text-4xl font-bold text-white mb-4\",\"children\":\"Mechanism of Action\"}],[\"$\",\"div\",null,{\"className\":\"space-y-3 mb-8\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-start gap-3\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":20,\"height\":20,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-circle-check-big text-blue-400 mt-1\",\"children\":[[\"$\",\"path\",\"yps3ct\",{\"d\":\"M21.801 10A10 10 0 1 1 17 3.335\"}],[\"$\",\"path\",\"1pflzl\",{\"d\":\"m9 11 3 3L22 4\"}],\"$undefined\"]}],[\"$\",\"p\",null,{\"className\":\"text-2xl\",\"children\":\"Human IgG1 monoclonal antibody targeting PD-L1\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-start gap-3\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":20,\"height\":20,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-circle-check-big text-blue-400 mt-1\",\"children\":[[\"$\",\"path\",\"yps3ct\",{\"d\":\"M21.801 10A10 10 0 1 1 17 3.335\"}],[\"$\",\"path\",\"1pflzl\",{\"d\":\"m9 11 3 3L22 4\"}],\"$undefined\"]}],[\"$\",\"p\",null,{\"className\":\"text-2xl\",\"children\":\"Dual action: Blocks PD-L1/PD-1 and PD-L1/B7.1 interactions\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-start gap-3\",\"children\":[[\"$\",\"svg\",null,{\"xmlns\":\"http://www.w3.org/2000/svg\",\"width\":20,\"height\":20,\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":2,\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\",\"className\":\"lucide lucide-circle-check-big text-blue-400 mt-1\",\"children\":[[\"$\",\"path\",\"yps3ct\",{\"d\":\"M21.801 10A10 10 0 1 1 17 3.335\"}],[\"$\",\"path\",\"1pflzl\",{\"d\":\"m9 11 3 3L22 4\"}],\"$undefined\"]}],[\"$\",\"p\",null,{\"className\":\"text-2xl\",\"children\":\"Induces antibody-dependent cell-mediated cytotoxicity (ADCC)\"}]]}]]}],[\"$\",\"h4\",null,{\"className\":\"text-4xl font-bold text-white mb-4\",\"children\":\"Clinical Efficacy (Study CK-301-101)\"}],[\"$\",\"div\",null,{\"className\":\"grid grid-cols-2 gap-4 mb-8\",\"children\":[[\"$\",\"div\",null,{\"className\":\"bg-slate-700/50 p-4 rounded-lg\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xl text-gray-300\",\"children\":\"Metastatic cSCC ORR\"}],[\"$\",\"p\",null,{\"className\":\"text-3xl font-bold text-green-400\",\"children\":\"47%\"}]]}],[\"$\",\"div\",null,{\"className\":\"bg-slate-700/50 p-4 rounded-lg\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xl text-gray-300\",\"children\":\"Locally Advanced ORR\"}],[\"$\",\"p\",null,{\"className\":\"text-3xl font-bold text-green-400\",\"children\":\"48%\"}]]}],[\"$\",\"div\",null,{\"className\":\"bg-slate-700/50 p-4 rounded-lg\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xl text-gray-300\",\"children\":\"Median Duration (Met)\"}],[\"$\",\"p\",null,{\"className\":\"text-2xl font-bold text-green-400\",\"children\":\"Not reached\"}]]}],[\"$\",\"div\",null,{\"className\":\"bg-slate-700/50 p-4 rounded-lg\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xl text-gray-300\",\"children\":\"12-Month Response\"}],[\"$\",\"p\",null,{\"className\":\"text-2xl font-bold text-green-400\",\"children\":\"75.4% / 88.2%\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"space-y-4\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-2xl font-bold text-white mb-2\",\"children\":\"Indication:\"}],[\"$\",\"p\",null,{\"className\":\"text-xl text-gray-300\",\"children\":\"Metastatic or locally advanced cutaneous squamous cell carcinoma in adults not candidates for curative surgery or radiation\"}]]}],[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-2xl font-bold text-white mb-2\",\"children\":\"Dosing:\"}],[\"$\",\"p\",null,{\"className\":\"text-xl text-gray-300\",\"children\":\"1,200 mg IV infusion every 3 weeks\"}]]}]]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"flex-none p-4 text-right\",\"children\":[\"$\",\"p\",null,{\"className\":\"text-xl text-gray-400\",\"children\":\"3\"}]}]]}]}],null],null],null]},[null,[\"$\",\"$L5\",null,{\"parallelRouterKey\":\"children\",\"segmentPath\":[\"children\",\"pages\",\"children\",\"3\",\"children\"],\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L6\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"notFoundStyles\":\"$undefined\"}]],null]},[null,[\"$\",\"$L5\",null,{\"parallelRouterKey\":\"children\",\"segmentPath\":[\"children\",\"pages\",\"children\"],\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L6\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"notFoundStyles\":\"$undefined\"}]],null]},[[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/8d323862949ffad9.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\"}]],[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"dark\",\"children\":[\"$\",\"body\",null,{\"className\":\"__className_f367f3 h-1080px w-1920px\",\"children\":[[\"$\",\"$7\",null,{\"fallback\":null,\"children\":[[\"$\",\"$L8\",null,{}],[\"$\",\"$L9\",null,{}]]}],[\"$\",\"$L5\",null,{\"parallelRouterKey\":\"children\",\"segmentPath\":[\"children\"],\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L6\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"title\",null,{\"children\":\"404: This page could not be found.\"}],[\"$\",\"div\",null,{\"style\":{\"fontFamily\":\"system-ui,\\\"Segoe UI\\\",Roboto,Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\"\",\"height\":\"100vh\",\"textAlign\":\"center\",\"display\":\"flex\",\"flexDirection\":\"column\",\"alignItems\":\"center\",\"justifyContent\":\"center\"},\"children\":[\"$\",\"div\",null,{\"children\":[[\"$\",\"style\",null,{\"dangerouslySetInnerHTML\":{\"__html\":\"body{color:#000;background:#fff;margin:0}.next-error-h1{border-right:1px solid rgba(0,0,0,.3)}@media (prefers-color-scheme:dark){body{color:#fff;background:#000}.next-error-h1{border-right:1px solid rgba(255,255,255,.3)}}\"}}],[\"$\",\"h1\",null,{\"className\":\"next-error-h1\",\"style\":{\"display\":\"inline-block\",\"margin\":\"0 20px 0 0\",\"padding\":\"0 23px 0 0\",\"fontSize\":24,\"fontWeight\":500,\"verticalAlign\":\"top\",\"lineHeight\":\"49px\"},\"children\":\"404\"}],[\"$\",\"div\",null,{\"style\":{\"display\":\"inline-block\"},\"children\":[\"$\",\"h2\",null,{\"style\":{\"fontSize\":14,\"fontWeight\":400,\"lineHeight\":\"49px\",\"margin\":0},\"children\":\"This page could not be found.\"}]}]]}]}]],\"notFoundStyles\":[]}]]}]}]],null],null],\"couldBeIntercepted\":false,\"initialHead\":[null,\"$La\"],\"globalErrorComponent\":\"$b\",\"missingSlots\":\"$Wc\"}]\n"])</script><script>self.__next_f.push([1,"a:[[\"$\",\"meta\",\"0\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1\"}],[\"$\",\"meta\",\"1\",{\"charSet\":\"utf-8\"}],[\"$\",\"title\",\"2\",{\"children\":\"Unloxcyt Market Survey - Interactive Presentation\"}],[\"$\",\"meta\",\"3\",{\"name\":\"description\",\"content\":\"Comprehensive market analysis of Cosibelimab-ipdl for advanced cSCC\"}],[\"$\",\"meta\",\"4\",{\"name\":\"next-size-adjust\"}]]\n4:null\n"])</script></body></html>